AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Abstracts highlight epetraborole's potential beneficial effects on hematological profile across clinical and nonclinical studies
MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas.
"These abstracts provide insights into the potential beneficial hematological effects of epetraborole across both clinical and nonclinical studies and strengthen our understanding of the exposure-response relationships that we believe support its development in polycythemia vera," said George H. Talbot, M.D. Co-Founder and Senior Medical Advisor of AN2 Therapeutics.
Key Highlights:
Clinical and nonclinical studies demonstrated potential beneficial effects of epetraborole on erythropoiesis and hemoglobin-related parameters.
Data further characterized the hematological and safety profile of epetraborole across healthy volunteers, non-PV patients, and nonhuman primate models.
Exposure-response relationships observed in nonhuman primates were predictive of effects subsequently observed in humans, supporting the translational relevance of these models.
Collectively, the findings support the ongoing clinical development of epetraborole as a potential oral treatment for PV.
SOHO 2026 Abstracts:
| Poster Number | Title |
| MPN-1041 | Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects |
| MPN-1076 | Hematological and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population |
| MPN-1082 | Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships |
| MPN-1106 | Hematological Profile in Nonhuman Primates of Epetraborole, a Novel Boron-Containing Candidate for Oral Treatment of Polycythemia Vera |
Copies of the abstracts will be available on the Presentations and Publications section of the AN2 Therapeutics website at the following link: https://www.an2therapeutics.com/pipeline/#presentations
About AN2 Therapeutics